Novel Applications of MICA-Binding Fusion Molecules
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of anti-MICA antigen binding fragments to address pressing issues in water quality, skin conditions, respiratory diseases, agriculture, and food safety, opening up new avenues for innovation and commercialization.
Background and Problem Solved
The original patent disclosed anti-MICA antigen binding fragments, fusion molecules, cells, and methods of using them, primarily focused on natural killer cells and cancer therapy. However, the patent's limitations in terms of applicability and scope hindered its potential in other fields. This inventive concept solves this problem by applying the core technology to entirely new industries and use cases, capitalizing on the versatility and adaptability of MICA-binding fusion molecules.
Detailed Description of the Inventive Concept
The new claims encompass a system for monitoring and controlling water quality, a method for reducing inflammation in skin conditions, a device for diagnosing and treating respiratory diseases, a method for enhancing crop yields, and a system for detecting and preventing foodborne illnesses. Each of these applications leverages the MICA-binding fusion molecule's ability to detect and neutralize specific targets, providing innovative solutions to pressing problems in their respective fields.
Novelty and Inventive Step
The novelty of this inventive concept lies in its application of the anti-MICA antigen binding fragments to entirely new industries and use cases, demonstrating an inventive step beyond the original patent's scope. The new claims introduce unexpected and non-obvious uses for the core technology, expanding its potential for commercialization and impact.
Alternative Embodiments and Variations
Alternative embodiments of this inventive concept could include the development of MICA-binding fusion molecules with tailored specificity for different applications, the integration of these molecules with existing technologies, or the exploration of new delivery methods and formulations. Variations could involve adapting the core technology to address related problems within each industry, such as using MICA-binding fusion molecules to detect and treat other waterborne pathogens or to monitor and control air quality.
Potential Commercial Applications and Market
The commercial potential of this inventive concept is vast, with applications in water quality management, skin care, respiratory disease diagnosis and treatment, agriculture, and food safety. The target industries include water treatment, pharmaceuticals, medical devices, agriculture, and food processing, with potential partnerships and collaborations with companies, research institutions, and government agencies.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and immunological engineering, focusing on antigen binding fragments, chimeric antigen receptors (CARs), and molecular targeting strategies for cellular interactions
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in molecular biology or bioengineering, experienced in antibody engineering, receptor interactions, and therapeutic molecule design, familiar with techniques for modifying protein binding domains and exploring novel applications of targeted molecular technologies
Obviousness Rationale
A person having ordinary skill in the art would recognize that the MICA-binding fusion molecule's core technology from the source patent provides a versatile platform for developing targeted interventions across multiple domains. The fundamental mechanism of specific molecular binding can be readily adapted to different environmental and biological contexts by applying standard biotechnological techniques. The PTD's variations represent predictable extensions of the original molecular targeting strategy, utilizing well-established principles of protein engineering and receptor interactions.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,571 |
|---|---|
| Title | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| Assignee(s) | The Trustees of Dartmouth College |